Top

29-04-2024 | Lymphoma | Review Article

What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?

Authors: Ayoma D. Attygalle, John K. C. Chan, Sarah E. Coupland, Ming-Qing Du, Judith A. Ferry, Daphne de Jong, Dita Gratzinger, Megan S. Lim, Alina Nicolae, German Ott, Andreas Rosenwald, Anna Schuh, Reiner Siebert, on behalf of the WHO 5th Edition Classification Project

Published in: Journal of Hematopathology

Abstract

The classification of tumors is essential in the diagnosis and clinical management of patients with malignant neoplasms. The World Health Organization (WHO) provides a globally applicable classification scheme of neoplasms and it was updated several times. In this review, we briefly outline the cornerstones of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours on lymphoid neoplasms. As is adopted throughout the 5th edition of the WHO classification of tumors of all organ systems, entities are listed by a hierarchical system. For the first time, tumor-like lesions have been included in the classification, and modifications of nomenclature for some entities, revisions of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities are presented along with mesenchymal lesions specific to the stroma of lymph nodes and the spleen. In addition to specific outlines on constitutional and somatic genetic changes associated with given entities, a separate chapter on germline predisposition syndromes related to hematologic neoplasms has been added.

Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720–1748. https://doi.org/10.1038/s41375-022-01620-2CrossRefPubMedPubMedCentral

Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36:1703–1719. https://doi.org/10.1038/s41375-022-01613-1CrossRefPubMedPubMedCentral

Giné E, Martinez A, Villamor N et al (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95:1526–1533. https://doi.org/10.3324/haematol.2010.022277CrossRefPubMedPubMedCentral

El Hussein S, Khoury JD, Medeiros LJ (2021) B-prolymphocytic leukemia: is it time to retire this entity? Ann Diagn Pathol 54:151790. https://doi.org/10.1016/j.anndiagpath.2021.151790CrossRefPubMed

Siebert R, Schuh A, Ott G et al (2023) Response to the comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the world health organization classification of haematolymphoid tumors. Leukemia 37:1170–1172. https://doi.org/10.1038/s41375-023-01872-6CrossRefPubMedPubMedCentral

Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331–1344. https://doi.org/10.1056/NEJMoa1614598CrossRefPubMed

Hiddemann W, Barbui AM, Canales MA et al (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36:2395–2404. https://doi.org/10.1200/JCO.2017.76.8960CrossRefPubMed

Rimsza LM, Li H, Braziel RM et al (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151–e153. https://doi.org/10.3324/haematol.2017.175059CrossRefPubMedPubMedCentral

Morschhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 379:934–947. https://doi.org/10.1056/NEJMoa1805104CrossRefPubMedPubMedCentral

10.

Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37:2815–2824. https://doi.org/10.1200/JCO.19.01073CrossRefPubMedPubMedCentral

11.

Zamò A, Gerhard-Hartmann E, Ott G et al (2022) Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series. Virchows Arch 481:935–943. https://doi.org/10.1007/s00428-022-03420-6CrossRefPubMedPubMedCentral

12.

Nann D, Ramis-Zaldivar JE, Müller I et al (2020) Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Adv 4:5652–5665. https://doi.org/10.1182/bloodadvances.2020002944CrossRefPubMedPubMedCentral

13.

Schmidt J, Gong S, Marafioti T et al (2016) Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 128:1101–1111. https://doi.org/10.1182/blood-2016-03-703819CrossRefPubMedPubMedCentral

14.

El Behery R, Laurini JA, Weisenburger DD et al (2018) Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma. Hum Pathol 72:180–190. https://doi.org/10.1016/j.humpath.2017.11.002CrossRefPubMed

15.

Laurent C, Adélaïde J, Guille A et al (2021) High-grade follicular lymphomas exhibit clinicopathologic, cytogenetic, and molecular diversity extending beyond grades 3A and 3B. Am J Surg Pathol 45:1324–1336. https://doi.org/10.1097/PAS.0000000000001726CrossRefPubMed

16.

Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50:74–87. https://doi.org/10.1016/j.pathol.2017.09.006CrossRefPubMed

17.

Pasqualucci L, Dalla-Favera R (2018) Genetics of diffuse large B-cell lymphoma. Blood 131:2307–2319. https://doi.org/10.1182/blood-2017-11-764332CrossRefPubMedPubMedCentral

18.

Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. https://doi.org/10.1182/blood-2003-05-1545CrossRefPubMed

19.

Runge HFP, Lacy S, Barrans S et al (2021) Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL). Br J Haematol 192:216–220. https://doi.org/10.1111/bjh.17132CrossRefPubMed

20.

Scott DW, Wright GW, Williams PM et al (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214–1217. https://doi.org/10.1182/blood-2013-11-536433CrossRefPubMedPubMedCentral

21.

Chapuy B, Stewart C, Dunford AJ et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679–690. https://doi.org/10.1038/s41591-018-0016-8CrossRefPubMedPubMedCentral

22.

Wright GW, Da Huang W, Phelan JD et al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37:551-568.e14. https://doi.org/10.1016/j.ccell.2020.03.015CrossRefPubMedPubMedCentral

23.

Salaverria I, Philipp C, Oschlies I et al (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 118:139–147. https://doi.org/10.1182/blood-2011-01-330795CrossRefPubMed

24.

Ramis-Zaldivar JE, Gonzalez-Farré B, Balagué O et al (2020) Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood 135:274–286. https://doi.org/10.1182/blood.2019002699CrossRefPubMedPubMedCentral

25.

Salaverria I, Martin-Guerrero I, Wagener R et al (2014) A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 123:1187–1198. https://doi.org/10.1182/blood-2013-06-507996CrossRefPubMedPubMedCentral

26.

Horn H, Kalmbach S, Wagener R et al (2021) A diagnostic approach to the identification of Burkitt-like lymphoma with 11q aberration in aggressive B-cell lymphomas. Am J Surg Pathol 45:356–364. https://doi.org/10.1097/PAS.0000000000001613CrossRefPubMed

27.

Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J et al (2019) Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 104:1822–1829. https://doi.org/10.3324/haematol.2018.207928CrossRefPubMedPubMedCentral

28.

Wagener R, Seufert J, Raimondi F et al (2019) The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 133:962–966. https://doi.org/10.1182/blood-2018-07-864025CrossRefPubMedPubMedCentral

29.

Rosenthal A, Younes A (2017) High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev 31:37–42. https://doi.org/10.1016/j.blre.2016.09.004CrossRefPubMed

30.

Scott DW, King RL, Staiger AM et al (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060–2064. https://doi.org/10.1182/blood-2017-12-820605CrossRefPubMedPubMedCentral

31.

Copie-Bergman C, Cuillière-Dartigues P, Baia M et al (2015) MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood 126:2466–2474. https://doi.org/10.1182/blood-2015-05-647602CrossRefPubMed

32.

Rosenwald A, Bens S, Advani R et al (2019) Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 37:3359–3368. https://doi.org/10.1200/JCO.19.00743CrossRefPubMed

33.

Zhang C, Stelloo E, Barrans S et al (2024) Non-IG:MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential. Leukemia. https://doi.org/10.1038/s41375-023-02134-1CrossRefPubMedPubMedCentral

34.

Coupland SE, Du M-Q, Ferry JA et al (2024) The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research. J Pathol 262:255–270. https://doi.org/10.1002/path.6246CrossRefPubMed

35.

Snuderl M, Kolman OK, Chen Y-B et al (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34:327–340. https://doi.org/10.1097/PAS.0b013e3181cd3aebCrossRefPubMedPubMedCentral

36.

Evrard SM, Péricart S, Grand D et al (2019) Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Haematologica 104:e154–e157. https://doi.org/10.3324/haematol.2018.198572CrossRefPubMedPubMedCentral

37.

Cucco F, Barrans S, Sha C et al (2020) Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia 34:1329–1341. https://doi.org/10.1038/s41375-019-0691-6CrossRefPubMed

38.

Alexanian S, Said J, Lones M et al (2013) KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states. Am J Surg Pathol 37:241–249. https://doi.org/10.1097/PAS.0b013e318267fabcCrossRefPubMedPubMedCentral

39.

Collinge B, Ben-Neriah S, Chong L et al (2021) The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood 137:2196–2208. https://doi.org/10.1182/blood.2020007193CrossRefPubMed

40.

Weniger MA, Küppers R (2021) Molecular biology of Hodgkin lymphoma. Leukemia 35:968–981. https://doi.org/10.1038/s41375-021-01204-6CrossRefPubMedPubMedCentral

41.

Piris MA, Medeiros LJ, Chang K-C (2020) Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology 52:154–165. https://doi.org/10.1016/j.pathol.2019.09.005CrossRefPubMed

42.

Sarkozy C, Hung SS, Chavez EA et al (2021) Mutational landscape of gray zone lymphoma. Blood 137:1765–1776. https://doi.org/10.1182/blood.2020007507CrossRefPubMed

43.

Campo E, Jaffe ES (2021) Taking gray zone lymphomas out of the shadows. Blood 137:1703–1704. https://doi.org/10.1182/blood.2020009265CrossRefPubMedPubMedCentral

44.

Traverse-Glehen A, Pittaluga S, Gaulard P et al (2005) Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29:1411–1421. https://doi.org/10.1097/01.pas.0000180856.74572.73CrossRefPubMed

45.

Sarkozy C, Copie-Bergman C, Damotte D et al (2019) Gray-zone lymphoma between cHL and large B-cell lymphoma: a histopathologic series from the LYSA. Am J Surg Pathol 43:341–351. https://doi.org/10.1097/PAS.0000000000001198CrossRefPubMed

46.

Pittaluga S, Nicolae A, Wright GW et al (2020) Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma. Blood Cancer Discov 1:155–161. https://doi.org/10.1158/2643-3230.BCD-20-0009CrossRefPubMedPubMedCentral

47.

Eberle FC, Rodriguez-Canales J, Wei L et al (2011) Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96:558–566. https://doi.org/10.3324/haematol.2010.033167CrossRefPubMedPubMedCentral

48.

Dunleavy K, Wilson WH (2015) Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood 125:33–39. https://doi.org/10.1182/blood-2014-05-575092CrossRefPubMedPubMedCentral

49.

Steidl C (2017) Exposing Hodgkin-Reed-Sternberg cells. Blood 129:6–7. https://doi.org/10.1182/blood-2016-11-746701CrossRefPubMed

50.

Wienand K, Chapuy B, Stewart C et al (2019) Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv 3:4065–4080. https://doi.org/10.1182/bloodadvances.2019001012CrossRefPubMedPubMedCentral

51.

Chetaille B, Bertucci F, Finetti P et al (2009) Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113:2765–3775. https://doi.org/10.1182/blood-2008-07-168096CrossRefPubMed

52.

de Jong D, Roemer MGM, Chan JKC et al (2017) B-cell and classical Hodgkin lymphomas associated with immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2. Am J Clin Pathol 147:153–170. https://doi.org/10.1093/ajcp/aqw216CrossRefPubMedPubMedCentral

53.

Dojcinov SD, Venkataraman G, Raffeld M et al (2010) EBV positive mucocutaneous ulcer–a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 34:405–417. https://doi.org/10.1097/PAS.0b013e3181cf8622CrossRefPubMedPubMedCentral

54.

Dojcinov SD, Venkataraman G, Pittaluga S et al (2011) Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 117:4726–4735. https://doi.org/10.1182/blood-2010-12-323238CrossRefPubMedPubMedCentral

55.

Nicolae A, Pittaluga S, Venkataraman G et al (2013) Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol 37:816–826. https://doi.org/10.1097/PAS.0b013e3182785610CrossRefPubMedPubMedCentral

56.

Campo E, Jaffe ES, Cook JR et al (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140:1229–1253. https://doi.org/10.1182/blood.2022015851CrossRefPubMedPubMedCentral

57.

Nam-Cha SH, Montes-Moreno S, Salcedo MT et al (2009) Lymphocyte-rich classical Hodgkin’s lymphoma: distinctive tumor and microenvironment markers. Mod Pathol 22:1006–1015. https://doi.org/10.1038/modpathol.2009.54CrossRefPubMed

58.

Hartmann S, Plütschow A, Mottok A et al (2019) The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. Am J Hematol 94:1208–1213. https://doi.org/10.1002/ajh.25607CrossRefPubMed

59.

Randen U, Trøen G, Tierens A et al (2014) Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica 99:497–504. https://doi.org/10.3324/haematol.2013.091702CrossRefPubMedPubMedCentral

60.

Małecka A, Trøen G, Tierens A et al (2018) Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br J Haematol 183:838–842. https://doi.org/10.1111/bjh.15063CrossRefPubMed

61.

Leung N, Bridoux F, Nasr SH (2021) Monoclonal gammopathy of renal significance. N Engl J Med 384:1931–1941. https://doi.org/10.1056/NEJMra1810907CrossRefPubMed

62.

Wahner-Roedler DL, Kyle RA (2005) Heavy chain diseases. Best Pract Res Clin Haematol 18:729–746. https://doi.org/10.1016/j.beha.2005.01.029CrossRefPubMed

63.

Natkunam Y, Gratzinger D, Chadburn A et al (2018) Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood 132:1871–1878. https://doi.org/10.1182/blood-2018-04-842559CrossRefPubMedPubMedCentral

64.

Tangye SG, Al-Herz W, Bousfiha A et al (2022) Human inborn errors of immunity: 2022 update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 42:1473–1507. https://doi.org/10.1007/s10875-022-01289-3CrossRefPubMedPubMedCentral

65.

Morscio J, Finalet Ferreiro J, Vander Borght S et al (2017) Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma. Mod Pathol 30:370–381. https://doi.org/10.1038/modpathol.2016.199CrossRefPubMed

66.

Yu M, Hazelton WD, Luebeck GE et al (2020) Epigenetic aging: more than just a clock when it comes to cancer. Cancer Res 80:367–374. https://doi.org/10.1158/0008-5472.CAN-19-0924CrossRefPubMed

67.

Nicolae A, Pittaluga S, Abdullah S et al (2015) EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 126:863–872. https://doi.org/10.1182/blood-2015-02-630632CrossRefPubMedPubMedCentral

68.

Marcelis L, Berghen C, de Zutter A et al (2018) Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases. Mod Pathol 31:1457–1469. https://doi.org/10.1038/s41379-018-0054-2CrossRefPubMed

69.

Seidel MG, Kindle G, Gathmann B et al (2019) The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract 7:1763–1770. https://doi.org/10.1016/j.jaip.2019.02.004CrossRefPubMed

70.

Steinhilber J, Mederake M, Bonzheim I et al (2019) The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations. Mod Pathol 32:1123–1134. https://doi.org/10.1038/s41379-019-0254-4CrossRefPubMed

71.

de Leval L, Parrens M, Le Bras F et al (2015) Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica 100:e361–e364. https://doi.org/10.3324/haematol.2015.126300CrossRefPubMedPubMedCentral

72.

Attygalle AD, Chuang S-S, Diss TC et al (2007) Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology 50:498–508. https://doi.org/10.1111/j.1365-2559.2007.02632.xCrossRefPubMed

73.

Hsi ED, Said J, Macon WR et al (2014) Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol 38:768–775. https://doi.org/10.1097/PAS.0000000000000188CrossRefPubMedPubMedCentral

74.

Tokunaga T, Shimada K, Yamamoto K et al (2012) Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119:2837–2843. https://doi.org/10.1182/blood-2011-08-374371CrossRefPubMed

75.

Sakata-Yanagimoto M, Enami T, Yoshida K et al (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171–175. https://doi.org/10.1038/ng.2872CrossRefPubMed

76.

Wang C, McKeithan TW, Gong Q et al (2015) IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126:1741–1752. https://doi.org/10.1182/blood-2015-05-644591CrossRefPubMedPubMedCentral

77.

Schwartz FH, Cai Q, Fellmann E et al (2017) TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. J Pathol 242:129–133. https://doi.org/10.1002/path.4898CrossRefPubMed

78.

Yao W-Q, Wu F, Zhang W et al (2020) Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol 250:346–357. https://doi.org/10.1002/path.5376CrossRefPubMedPubMedCentral

79.

Attygalle AD, Dobson R, Chak PK et al (2022) Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis. Histopathology 80:847–858. https://doi.org/10.1111/his.14619CrossRefPubMedPubMedCentral

80.

Iqbal J, Wright G, Wang C et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915–2923. https://doi.org/10.1182/blood-2013-11-536359CrossRefPubMedPubMedCentral

81.

Parrilla Castellar ER, Jaffe ES, Said JW et al (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473–1480. https://doi.org/10.1182/blood-2014-04-571091CrossRefPubMedPubMedCentral

82.

Pedersen MB, Hamilton-Dutoit SJ, Bendix K et al (2017) DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood 130:554–557. https://doi.org/10.1182/blood-2016-12-755496CrossRefPubMedPubMedCentral

83.

Hapgood G, Ben-Neriah S, Mottok A et al (2019) Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol 186:e28–e31. https://doi.org/10.1111/bjh.15860CrossRefPubMedPubMedCentral

84.

Boi M, Rinaldi A, Kwee I et al (2013) PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood 122:2683–2693. https://doi.org/10.1182/blood-2013-04-497933CrossRefPubMed

85.

Liang H-C, Costanza M, Prutsch N et al (2021) Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma. Nat Commun 12:5577. https://doi.org/10.1038/s41467-021-25379-9CrossRefPubMedPubMedCentral

86.

King RL, Dao LN, McPhail ED et al (2016) Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements. Am J Surg Pathol 40:36–43. https://doi.org/10.1097/PAS.0000000000000500CrossRefPubMedPubMedCentral

87.

Feldman AL, Oishi N, Ketterling RP et al (2022) Immunohistochemical approach to genetic subtyping of anaplastic large cell lymphoma. Am J Surg Pathol 46:1490–1499. https://doi.org/10.1097/PAS.0000000000001941CrossRefPubMedPubMedCentral

88.

Fitzpatrick MJ, Massoth LR, Marcus C et al (2021) JAK2 rearrangements are a recurrent alteration in CD30+ systemic T-cell lymphomas with anaplastic morphology. Am J Surg Pathol 45:895–904. https://doi.org/10.1097/PAS.0000000000001708CrossRefPubMed

89.

Scarfò I, Pellegrino E, Mereu E et al (2016) Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood 127:221–232. https://doi.org/10.1182/blood-2014-12-614503CrossRefPubMed

90.

Fang H, Beird HC, Wang SA et al (2023) T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis. Leukemia 37:1919–1921. https://doi.org/10.1038/s41375-023-01956-3CrossRefPubMed

91.

Gutierrez M, Bladek P, Goksu B et al (2023) T-cell prolymphocytic leukemia: diagnosis, pathogenesis, and treatment. Int J Mol Sci 24. https://doi.org/10.3390/ijms241512106

92.

Kawamoto K, Miyoshi H, Yanagida E et al (2017) Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. Eur J Haematol 98:459–466. https://doi.org/10.1111/ejh.12856CrossRefPubMed

93.

Schrader A, Crispatzu G, Oberbeck S et al (2018) Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun 9:697. https://doi.org/10.1038/s41467-017-02688-6CrossRefPubMedPubMedCentral

94.

Mitteldorf C, Stadler R, Sander CA et al (2018) Folliculotropic mycosis fungoides. J Dtsch Dermatol Ges 16:543–557. https://doi.org/10.1111/ddg.13514CrossRefPubMed

95.

Kempf W, Kerl K, Mitteldorf C (2018) Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 37:24–29. https://doi.org/10.12788/j.sder.2018.001CrossRefPubMed

96.

Csikesz CR, Knudson RA, Greipp PT et al (2013) Primary cutaneous CD30-positive T-cell lymphoproliferative disorders with biallelic rearrangements of DUSP22. J Invest Dermatol 133:1680–1682. https://doi.org/10.1038/jid.2013.22CrossRefPubMed

97.

Vasmatzis G, Johnson SH, Knudson RA et al (2012) Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 120:2280–2289. https://doi.org/10.1182/blood-2012-03-419937CrossRefPubMedPubMedCentral

98.

Velusamy T, Kiel MJ, Sahasrabuddhe AA et al (2014) A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 124:3768–3771. https://doi.org/10.1182/blood-2014-07-588434CrossRefPubMed

99.

Díaz La, de Pinta FJ, Rodríguez Moreno M, Salgado RN et al (2023) Anaplastic large cell lymphomas with the 6p25.3 rearrangement are a heterogeneous group of tumours with a diverse molecular background. Hum Pathol 137:71–78. https://doi.org/10.1016/j.humpath.2023.04.015CrossRef

100.

Kempf W, Petrella T, Willemze R et al (2022) Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop. Br J Dermatol 186:887–897. https://doi.org/10.1111/bjd.20973CrossRefPubMed

101.

Willemze R, Cerroni L, Kempf W et al (2019) The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133:1703–1714. https://doi.org/10.1182/blood-2018-11-881268CrossRefPubMedPubMedCentral

102.

Kempf W, Mitteldorf C (2021) Cutaneous T-cell lymphomas-an update 2021. Hematol Oncol 39(Suppl 1):46–51. https://doi.org/10.1002/hon.2850CrossRefPubMed

103.

Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390. https://doi.org/10.1182/blood-2016-01-643569CrossRefPubMedPubMedCentral

104.

Polprasert C, Takeuchi Y, Kakiuchi N et al (2019) Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Adv 3:588–595. https://doi.org/10.1182/bloodadvances.2018028340CrossRefPubMedPubMedCentral

105.

Koh J, Jang I, Mun S et al (2021) Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv 5:3919–3930. https://doi.org/10.1182/bloodadvances.2021004562CrossRefPubMedPubMedCentral

106.

Takeuchi K, Yokoyama M, Ishizawa S et al (2010) Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 116:5631–5637. https://doi.org/10.1182/blood-2010-06-290650CrossRefPubMed

107.

Mansoor A, Pittaluga S, Beck PL et al (2011) NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood 117:1447–1452. https://doi.org/10.1182/blood-2010-08-302737CrossRefPubMedPubMedCentral

108.

Xiao W, Gupta GK, Yao J et al (2019) Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood 134:986–991. https://doi.org/10.1182/blood.2019001443CrossRefPubMedPubMedCentral

109.

Jeon YK, Kim J-H, Sung J-Y et al (2015) Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features. Hum Pathol 46:981–990. https://doi.org/10.1016/j.humpath.2015.03.002CrossRefPubMed

110.

Jung KS, Cho S-H, Kim SJ et al (2016) Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma. Int J Hematol 104:591–595. https://doi.org/10.1007/s12185-016-2068-1CrossRefPubMed

111.

Ng S-B, Chung T-H, Kato S et al (2018) Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica 103:278–287. https://doi.org/10.3324/haematol.2017.180430CrossRefPubMedPubMedCentral

112.

Yamashita D, Shimada K, Takata K et al (2018) Reappraisal of nodal Epstein-Barr virus-negative cytotoxic T-cell lymphoma: identification of indolent CD5+ diseases. Cancer Sci 109:2599–2610. https://doi.org/10.1111/cas.13652CrossRefPubMedPubMedCentral

113.

Wai CMM, Chen S, Phyu T et al (2022) Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica 107:1864–1879. https://doi.org/10.3324/haematol.2021.280003CrossRefPubMedPubMedCentral

114.

Suster S, Rosai J (1989) Intranodal hemorrhagic spindle-cell tumor with “amianthoid” fibers. Report of six cases of a distinctive mesenchymal neoplasm of the inguinal region that simulates Kaposi’s sarcoma. Am J Surg Pathol 13:347–357CrossRefPubMed

115.

Weiss SW, Gnepp DR, Bratthauer GL (1989) Palisaded myofibroblastoma. A benign mesenchymal tumor of lymph node. Am J Surg Pathol 13:341–346CrossRefPubMed

116.

Laskin WB, Lasota JP, Fetsch JF et al (2015) Intranodal palisaded myofibroblastoma: another mesenchymal neoplasm with CTNNB1 (β-catenin gene) mutations: clinicopathologic, immunohistochemical, and molecular genetic study of 18 cases. Am J Surg Pathol 39:197–205. https://doi.org/10.1097/PAS.0000000000000299CrossRefPubMedPubMedCentral

117.

Falk S, Stutte HJ, Frizzera G (1991) Littoral cell angioma. A novel splenic vascular lesion demonstrating histiocytic differentiation. Am J Surg Pathol 15:1023–1033CrossRefPubMed

118.

Bi C, Jiang L, Li Z et al (2007) Littoral cell angioma of spleen: a clinicopathologic study of 17 cases. Zhonghua Bing Li Xue Za Zhi 36:239–243PubMed

119.

Peckova K, Michal M, Hadravsky L et al (2016) Littoral cell angioma of the spleen: a study of 25 cases with confirmation of frequent association with visceral malignancies. Histopathology 69:762–774. https://doi.org/10.1111/his.13026CrossRefPubMed

120.

Ogembo JG, Milner DA, Mansfield KG et al (2012) SIRPα/CD172a and FHOD1 are unique markers of littoral cells, a recently evolved major cell population of red pulp of human spleen. J Immunol 188:4496–4505. https://doi.org/10.4049/jimmunol.1103086CrossRefPubMed

121.

Donner LR, Marcussen S, Dobin SM (2005) A clonal dic(16;21)(p13.1;p11.2)del(16)(q11.1), with gains of several chromosomes and monosomy 21, in a case of splenic hamartoma: evidence for its neoplastic, not hamartomatous, origin. Cancer Genet Cytogenet 157:160–163. https://doi.org/10.1016/j.cancergencyto.2004.08.011CrossRefPubMed

122.

Chiu A, Czader M, Cheng L et al (2011) Clonal X-chromosome inactivation suggests that splenic cord capillary hemangioma is a true neoplasm and not a subtype of splenic hamartoma. Mod Pathol 24:108–116. https://doi.org/10.1038/modpathol.2010.168CrossRefPubMed

123.

Chang K-C, Lee J-C, Wang Y-C et al (2016) Polyclonality in sclerosing angiomatoid nodular transformation of the spleen. Am J Surg Pathol 40:1343–1351. https://doi.org/10.1097/PAS.0000000000000716CrossRefPubMed

124.

Uzun S, Özcan Ö, Işık A et al (2021) Loss of CTNNB1 exon 3 in sclerosing angiomatoid nodular transformation of the spleen. Virchows Arch 479:747–754. https://doi.org/10.1007/s00428-021-03064-yCrossRefPubMed

125.

Sim J, Ahn HI, Han H et al (2013) Splenic hamartoma: a case report and review of the literature. World J Clin Cases 1:217–219. https://doi.org/10.12998/wjcc.v1.i7.217CrossRefPubMedPubMedCentral

126.

Martel M, Cheuk W, Lombardi L et al (2004) Sclerosing angiomatoid nodular transformation (SANT): report of 25 cases of a distinctive benign splenic lesion. Am J Surg Pathol 28:1268–1279. https://doi.org/10.1097/01.pas.0000138004.54274.d3CrossRefPubMed

127.

Diebold J, Le Tourneau A, Marmey B et al (2008) Is sclerosing angiomatoid nodular transformation (SANT) of the splenic red pulp identical to inflammatory pseudotumour? Report of 16 cases. Histopathology 53:299–310. https://doi.org/10.1111/j.1365-2559.2008.03101.xCrossRefPubMed

128.

Liao J, Wang Z, Li Q et al (2021) CT and MRI features of sclerosing angiomatoid nodular transformation of the spleen: a report of 18 patients with pathologic correlation. Diagn Interv Imaging 102:389–396. https://doi.org/10.1016/j.diii.2021.01.003CrossRefPubMed

129.

Cheuk W, Lee AKC, Arora N et al (2005) Splenic hamartoma with bizarre stromal cells. Am J Surg Pathol 29:109–114. https://doi.org/10.1097/01.pas.0000146026.69082.68CrossRefPubMed

130.

Laskin WB, Alasadi R, Variakojis D (2005) Splenic hamartoma. Am J Surg Pathol 29:1114–1115CrossRefPubMed

131.

Yigit N, Covey S, Tam W (2015) Massive splenic hamartoma with bizarre stromal cells. Int J Hematol 101:315–316. https://doi.org/10.1007/s12185-015-1748-6CrossRefPubMed

132.

Cheng N, Chen J, Pan Y et al (2018) Splenic hamartoma with bizarre stromal cells: a case report and literature review. Diagn Pathol 13:8. https://doi.org/10.1186/s13000-018-0687-yCrossRefPubMedPubMedCentral

133.

Zukerberg LR, Kaynor BL, Silverman ML et al (1991) Splenic hamartoma and capillary hemangioma are distinct entities: immunohistochemical analysis of CD8 expression by endothelial cells. Hum Pathol 22:1258–1261. https://doi.org/10.1016/0046-8177(91)90108-2CrossRefPubMed

134.

Ali TZ, Beyer G, Taylor M et al (2005) Splenic hamartoma: immunohistochemical and ultrastructural profile of two cases. Int J Surg Pathol 13:103–111. https://doi.org/10.1177/106689690501300116CrossRefPubMed

135.

Bofill M, Akbar AN, Amlot PL (2000) Follicular dendritic cells share a membrane-bound protein with fibroblasts. J Pathol 191:217–226. https://doi.org/10.1002/(SICI)1096-9896(200006)191:2%3c217:AID-PATH586%3e3.0.CO;2-6CrossRefPubMed

136.

van Nierop K, de Groot C (2002) Human follicular dendritic cells: function, origin and development. Semin Immunol 14:251–257. https://doi.org/10.1016/s1044-5323(02)00057-xCrossRefPubMed

137.

Jarjour M, Jorquera A, Mondor I et al (2014) Fate mapping reveals origin and dynamics of lymph node follicular dendritic cells. J Exp Med 211:1109–1122. https://doi.org/10.1084/jem.20132409CrossRefPubMedPubMedCentral

138.

Jiang X-N, Zhang Y, Xue T et al (2021) New clinicopathologic scenarios of EBV+ inflammatory follicular dendritic cell sarcoma: report of 9 extrahepatosplenic cases. Am J Surg Pathol 45:765–772. https://doi.org/10.1097/PAS.0000000000001632CrossRefPubMed

139.

Pan S-T, Cheng C-Y, Lee N-S et al (2014) Follicular dendritic cell sarcoma of the inflammatory pseudotumor-like variant presenting as a colonic polyp. Korean J Pathol 48:140–145. https://doi.org/10.4132/KoreanJPathol.2014.48.2.140CrossRefPubMedPubMedCentral

140.

Ke X, He H, Zhang Q et al (2020) Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma presenting as a solitary colonic mass: two rare cases and a literature review. Histopathology 77:832–840. https://doi.org/10.1111/his.14169CrossRefPubMed

141.

Goh L, Teo NZ, Wang LM (2020) Beware the inflammatory cell-rich colonic polyp: a rare case of EBV-positive inflammatory pseudotumour-like follicular dendritic cell sarcoma with increased IgG4-positive plasma cells. Pathology 52:713–717. https://doi.org/10.1016/j.pathol.2020.05.011CrossRefPubMed

142.

He H, Xue Q, Tan F et al (2021) A rare case of primary pulmonary inflammatory pseudotumor-like follicular dendritic cell sarcoma successfully treated by lobectomy. Ann Transl Med 9:77. https://doi.org/10.21037/atm-20-4965CrossRefPubMedPubMedCentral

143.

Cheuk W, Chan JK, Shek TW et al (2001) Inflammatory pseudotumor-like follicular dendritic cell tumor: a distinctive low-grade malignant intra-abdominal neoplasm with consistent Epstein-Barr virus association. Am J Surg Pathol 25:721–731. https://doi.org/10.1097/00000478-200106000-00003CrossRefPubMed

144.

Li X-Q, Cheuk W, Lam PWY et al (2014) Inflammatory pseudotumor-like follicular dendritic cell tumor of liver and spleen: granulomatous and eosinophil-rich variants mimicking inflammatory or infective lesions. Am J Surg Pathol 38:646–653. https://doi.org/10.1097/PAS.0000000000000170CrossRefPubMed

Title: What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?
Authors: Ayoma D. Attygalle
John K. C. Chan
Sarah E. Coupland
Ming-Qing Du
Judith A. Ferry
Daphne de Jong
Dita Gratzinger
Megan S. Lim
Alina Nicolae
German Ott
Andreas Rosenwald
Anna Schuh
Reiner Siebert
on behalf of the WHO 5th Edition Classification Project
Publication date: 29-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
Epstein-Barr Virus
Published in: Journal of Hematopathology
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-024-00585-8

At a glance: The STEP trials

Springer Medicine

What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content